Stock IVBIY INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Market Closed - OTC Markets
Other stock markets
 02:13:26 2024-06-26 pm EDT 		5-day change 1st Jan Change
19.68 USD +0.92% Intraday chart for Innovent Biologics, Inc. -.--% -5.79%
Jul. 05 Innovent Biologics, Inc. and IASO Biotechnology Enhance Strategic Collaboration in Cell Therapy CI
Jul. 05 Nanjing IASO Biotherapeutics announced that it expects to receive funding from Innovent Biologics, Inc. CI

Evolution of the average Target Price on Innovent Biologics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d24eda6c1de8039.LmVeQFei9dJeGu2Y9rdrew5JxFBgcG7szSZgyZeK3S4.aRwveRzrwLMGXNTdvOE0KUkqpWcNNy2D_XYh_8TVrBdEFDV1CMfHkzJQtA~8c6c375fe3cbcd117fa4f0d8912b4fb0

Analyst Recommendations on Innovent Biologics, Inc.

Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy MT
Nomura Adjusts Innovent Biologics’ Price Target to HK$54.51 From HK$45.73, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.73 From SG$54.72, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$54.72 From HK$45.44, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.44 From HK$45.38, Keeps at Buy MT
UBS Adjusts Innovent Biologics' Price Target to HK$42 From HK$39.30, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.38 From HK$43.75, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$43.75 From HK$49.41, Keeps at Buy MT
UBS Adjusts Innovent Biologics' Price Target to HK$43 From HK$60, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$49.41 From HK$58.18, Keeps at Buy MT
Nomura Adjusts Innovent Biologics Price Target to HK$58.18 From HK$92.73, Keeps at Buy MT
INNOVENT BIOLOGICS : Nomura Adjusts Innovent's Price Target to HK$113.4 From HK$66.3, Keeps at Buy MT
Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
37.79 CNY
Average target price
51.95 CNY
Spread / Average Target
+37.47%
High Price Target
71.04 CNY
Spread / Highest target
+87.98%
Low Price Target
34.43 CNY
Spread / Lowest Target
-8.90%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Innovent Biologics, Inc.

Nomura
UBS

Ratings for Innovent Biologics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. IVBIY Stock
  5. Consensus Innovent Biologics, Inc.